The World’s only platform that can get patients on the right antibiotic therapy at the onset of their multi-drug resistant infection. Clinical studies demonstrate ultra-sensitivity and specificity. Accurate determination of effective antibiotics for multi-drug resistant infections in just 4 hours without culture, vs. 4 days. Detection of pathogens and toxins in 30 minutes. C. difficile study published in a top peer reviewed scientific journal. FDA submission Q3 2019, with clearance expected in Q1 2020.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Pathogen ID and AST
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):